On the role of GABA in anxiety and depression

Eksperimental'naya i Klinicheskaya Farmakologiya

Volumn 67, Issue 4, 2004, Pages 71-76

  Kaluev, A V ^a   Nutt, D J ^b,c  

^a Ctr for Physiol and Biochem Prob   (Ukraine)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; GABAERGIC RECEPTOR AFFECTING AGENT;

ANXIETY; DEPRESSION; HUMAN; MENTAL HEALTH; NEUROCHEMISTRY; NEUROPHYSIOLOGY; PATHOGENESIS; REVIEW; PHYSIOLOGY;

ANXIETY; DEPRESSION; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; HUMANS;

EID: 4644306896     PISSN: 08692092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. K. O. Alley and S. K. Kulkarni, Naunyn Schmiedebergs Arch. Pharmacol., 339(3), 306-311 (1989).
2. S. V. Argyropoulos and D. J. Nutt, Eur. Neuropsychopharm., 9(6), 407-412 (1999).
3. M. L. barbaccia, S. Lello, T. Sidiropoulou, et al., Psychoneuroendocrinol., 25, 659-675 (2000).
4. V. Benjamini, L. L. Skalitz, S. R. L. Joka and R. Andreatini, Eur. J. Pharmacol., 347, 23-27 (1998).
5. F. M. Besag, Drug Saf., 24(7), 513-536 (2001).
6. P. Boyer, Acta Psych Scand, 406, 24-29 (2000).
7. F. Borsini, S. Evangelista, and A. Meli, Eur. J. Pharmacol., 121(2), 265-268 (1986).
8. F. Borsini, A. mancinelli, V. D'Arkano, et al., Pharmacol. Biochem. Behav., 29(9), 275-279 (1988).
9. L. Chang, C. C. Cloak, and T. Ernst, J. Clin. Psych., 64(3), 7-14 (2003).
10. K. Chopra, J. Kunchandy, and S. K. Kulkarni, Arch. Int. Pharmacodyn. Thar., 294, 56-63 (1988).
11. R. J. Davidson, Biol. Psych., 51, 68-80 (2002).
12. M. Davis and P. J. Whalen, Mol. Psych., 6(1), 13-34 (2001).
13. R. C. Drugan, S. M. Paul, and J. N. Crawley, Brain Res., 631 (2), 270-276 (1993).
14. J. C. Do-Rego, C. Saudeau, and G. Chapouthier, J. Costentin, Pharmacol. Biochem. Behav., 72, 411-416 (2002).
15. W. C. Drevets, Ann. N. Y. Acad. Sci., 877, 614-637 (1999).
16. H. M. Emrich, D. V. Zervessen, W. Kissling, et al., Arch. Psych. Nervenkr., 229, 1-16 (1980).
17. E. Estrada-Camarena, C. M. Contreras, M. Saavedra, et al., Behav. Brain Res., 134, 175-183 (2002).
18. A. Fernandas Teruel, F. Boix, P. Escorihuela, et al., Eur. J. Pharmacol., 152(1-2), 1-7 (1988).
19. M. Freeman, S. A. Freeman, and S. L. McElroy, J. Affect. Disorders, 68, 1-23 (2002).
20. D. A. Finn, M. T. Rutledge-Gorman, and J. C. Crabbe, Neurogenet., 4, 109-135 (2003).
21. G. C. Y. Fong, B. M. Y. Cheung, and C. R. Kurama, Med. Prog., 2, 1-8 (2003).
22. W. S. Gilmer, Expert Opin. Pharmacother., 2(10), 1597-1608 (2001).
23. R. Gomez, C. R. Vargas, M. Wajner, and H. M. T. Barros, Brain Res., 968, 281-284 (2003).
24. M. S. George, A. Guidotti, D. Rubinov, et al., Biol. Psych., 35(10), 775-780 (1994).
25. S. N. Ghaemi, J. J. Katzow, S. P. Desai, and F. K. Goodwin, J. Clin. Psych., 59(8), 426-429 (1998).
26. A. Guidotti, Neuropharmacol., 30(12), 1425-1433 (1991).
27. T. Hayase, Y. Yamamoto, and K. Yamamoto, BMC Pharmacol., 2, 1-9 (2002).
28. J.P. Herman and A. Renda, B. Bodie, Biol. Psych., 53, 166-174 (2003).
29. K. Hirani, R. T. Khisti, and C. T. Chopde, Neuropharmacol., 43, 1339-1350 (2002).
30. A. M. Jasnow and K. L. Hubman, Brain Res., 920(1-2), 142-150 (2001).
31. S. R. L. Joka, L. L. Scalitz, V. Benjamini, et al., Eur. Neuropsychopharmacol., 10, 223-228 (2003).
32. A. V. Kalueff and D. J. Nutt, Depression Anxiety, 4, 100-110 (1996-1997).
33. J. P. Kelly, A. S. Wrynn, and B. E. Leonard, Pharmacol. Ther., 74(3), 299-316 (1997).
34. R. T. Khisti, S. N. Penland, M. J. VanDoren, et al., World J. Biol. Psych., 3, 87-95 (2000).
35. R. T. Khisti, C. T. Chopde, and S. P. Jain, Pharmacol. Biochem. Behav., 67, 137-143 (2000).
36. E. R. Korpi, G. Grunder, and H. Luddens, Prog. Neurobiol., 67, 113-159 (2003).
37. M. L. Kram, G. L. Kramer, M. Steciuk, et al., Neurosci. Res., 38, 193-198 (2000).
38. J. H. Krystal., G. sanacora, H. Blumberg, et al., Mol. Psych., 7, 71-80 (2002).
39. A. Kugaya, G. sanacora, N. P. L. G. Verhoeff, et al., Biol. Psych., 53, 1-8 (2003).
40. I. P. Lapin, CNS Drug Dev., 7(4), 471-481 (2001).
41. K. G. Lloyd, B. Zibkovic, D. Sanger, et al., J. Pharmacol. Exp. Ther. 241(1), 245-250 (1987).
42. K. G. Lloyd, B. Zibkovic, B. Skatton, et al., Prog. Neuropsychopharmacol. Biol. Psych., 13(3-4), 341-351 91989).
43. R. B. Lydiard, J. Clin. Psych., 64, 1-7 (2003).
44. R. Nesse, Neurosci Biobehav. Revs, 23, 895-903 (1999).
45. E. J. Nestler, E. Gould, H. Manji, et al., Biol. Psych., 52, 503-528 (2002).
46. H. Nishimura, Y. Ida, A. Tsuda, and M. Tanaka, Pharmacol. Biochem. Behav., 33(1), 227-231 (1989).
47. D. Nutt, Understanding Mental Health, Octopus Ltd, Bristol (2001), 1-3.
48. D. Nutt, Eur. Neuropsychopharm., 10(4), 433-437 (2001).
49. D. J. Nutt, J. C. ballender, D. Sheehan, and H. U. Whittchen, Int. J. Neuropsychopharmacol., 5, 315-325 (2002).
50. G. Obrocea, R. M. Dunn, M. A. Frye, et al., Biol. Psych., 51, 253-260 (2002).
51. F. Petty and A. D. Sherman, Pharmacol. Biochem. Behav., 18(4), 649-50 (1981).
52. F. Petty, J. Affect. Disorders, 34, 275-281 (1995).
53. R. M. Post, T. A. Ketter, K. Denicoff, et al., Psychopharmacol., 128(2), 115-129 (1996).
54. V. Raghavendra, G. Kaur, and S. K. Kulkarni, Eur. Neuropsychopharmacol., 10, 473-481 (2000).
55. D. Reddy, TINS, 24(3), 103-106 (2001).
56. L. Rago, R. A. Kiivet, A. Adojaan, et al., Pharmacol. Toxicol., 66(1), 41-44 (1990).
57. H. A. Ring, R. Crellin, S. Kirker and E. H. reynolds, J. Neurol. Neurosurg. Psych., 56(8), 925-928 (1993).
58. A. Roy, Neuropharmacol., 30(12), 1441-1444 (1991).
59. R. Rupprecht, Psychoneuroendocrinol., 28, 139-168 (2003).
60. G. sanacora, G. F. mason, D. L. Rothman, and J. H. Krystal, Am. J. Psych., 154(4), 663-665 (2002).
61. G. Sanacora, G. F. Mason, D. L. Rothman, et al., Am. J. Psych., 160(3), 577-579 (2003).
62. J. J. Sandford, S. V. Argyropoulos, and D. J. Nutt, Pharmacol. Ther., 88, 197-227 (2000).
63. Y. Sheline, Biol. Psych., 54, 338-352 (2003).
64. I. S. Shiah, L. N. Yatham., Y. C. Gau, and G. B. Baker, Prog. Neuropsychopharmacol. Biol. Psych., 27, 419-423 (1998).
65. S. Shibata, H. Nakanishi, S. Watanabe, and S. Ueki, Pharmacol. Biochem. Behav., 21(2), 225-230 (1984).
66. T. Skrebuhova, L. Alikmats, and V. Matto, Meth. Find. Exp. Clin. Pharmacol., 21(3), 173-178 (1999).
67. B. Spivak, R. Maayan, M. Kotler, et al., Psychol. Med., 30(5), 1227-1231 (2000).
68. I. Sundman-Erikkson, and P. Alard, J. Affect. Disorders, 71, 29-33 (2002).
69. I. Sundstrom Poromaa, S. Smith, and M. gulinello, Arch. Women Ment. Health, 6, 23-41 (2003).
70. G. Szymczyk and I. Zebrovska-Lupina, Pol. J. Pharmacol., 52(5), 337-344 (2000).
71. G. Tunnicliff and E. Malatynska, Neurochem. Res., 28(6), 965-976 (2003).
72. O. Yu. Vekovisheva, Academic Dissertation, Tampere (2003).
73. M. Uzunova, M. Ceci, C. Kohler, et al., Brain Res., 976, 1-8 (2003).
74. T. Yoshikawa, A. Watanabe, Y. Ishitsuka, et al., Genome Res., 4, 357-366 (2002).
75. D. A. Yurgelun-Todd, S. A. Gruber, G. Kanayama, et al., Bipolar Disorders, 2(3), 237-248 (2000).